Last updated on July 2017

A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)


Brief description of study

A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Detailed Study Description

The purpose of this Phase 2 study is:

  • To find out if the addition of nivolumab when given with veliparib in combination with platinum doublet chemotherapy extends the time your cancer is not getting worse compared to veliparib with platinum doublet chemotherapy alone. Platinum doublet chemotherapy is either carboplatin and paclitaxel or carboplatin and pemetrexed.
  • To find out if substances found in the blood and tumor tissue shows the effects of treatment with veliparib, nivolumab, and/or platinum doublet chemotherapy, or to help explain how to improve the treatment or diagnosis of cancer

    Clinical Study Identifier: TX151362

    Contact Investigators or Research Sites near you

    Start Over

    Nurdan Ilgaz

    Baptist Health Clinical Research Center & Lexington Cardiac Research Foundation
    Lexington, KY USA
      Connect »